Effect of Immunotherapy with the Monoclonal Antibody OC859 on Survival Rate and Immunoreaction of Patients with Ovarian Cancer

CHEN Rong,ZOU Ying,Huang Hui-fang,HUANG Rong-li,PAN Lin-ya,WU Ming,XU Xiu-ying,LIAN Li-juan
DOI: https://doi.org/10.3969/j.issn.1004-3845.2005.03.003
2005-01-01
Journal of reproductive medicine
Abstract:Objective: To evaluate the effect of the monoclonal antibody(MAb) OC_ 859 on the survival and immunoreaction of patients with ovarian cancer.Methods: 105 cases with MAbOC_ 859 therapy (MAb group) and 125 cases without MAbOC_ 859 therapy (control group) of ovarian cancer were studied retrospectively. Human anti-mouse antibody (HAMA) in 25 patients and the T cell subsets in 15 patients were also examined.Results: No significant differences were found in age, first cytoreductive surgery, FIGO staging, histological type and pathological grade between the MAb group and control group, but the mean number of chemotherapy courses in the MAb group was longer than that in the control group (10.9 vs 8.2 respectively, P0.01). The mean survival time in the MAb group and control group was (91±6) months and (62±7) months respectively; the 3-year survival rate, 65.7% and 41.1% respectively; the 5-year survival rate, 62.2% and 36.2% respectively (P0.001). HAMA titers were significantly elevated after MAbOC_ 859 treatment. The results showed that the ratio of CD_4/CD_8 in patients with ovarian cancer was much lower than that in women without the disease. It came to normal after one course of the MAbOC_ 859 therapy in majority of the patients and after two courses it became normal in all of the patients. Conclusion: The MAbOC_ 859 therapy significantly improved the survival and immunological responses of patients with ovarian cancer. These data suggest that the application of the MAbOC_ 859 has some therapeutic beneficial effects on patients with ovarian cancer.
What problem does this paper attempt to address?